Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1485)	1/5/2006 12:49:30 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

NUVO Opened with a good upgap this morning after it announced a collaboration agreement with Bayer HealthCare AG to develop of its alfimeprase, a thrombolytic agent which has been on P3 and has shown a good safety profile. The stock made a new 52wks. H as it traded above its Dec.2004 double top at the 11.23 level.<g> bigcharts.marketwatch.com It still needs to close above the Feb.2004 of 16.50 before it could try to test the 20 level.<g> bigcharts.marketwatch.com However, from a longer term perspective NUVO's chart remains "interesting".<g> bigcharts.marketwatch.com At the AHA in Dec. NUVO also reported on its P2a of rNAPc2, which has an acceptable safety profile and was well tolerated in doses up to 10 micrograms/kg in patients with ACS.(rNAPc2 is being studied in a P2 as a potential replacement for heparin in patients being treated for ACS.) Bernard